The rapid proliferation of cancer cells mandates a high protein turnover. The endoplasmic reticulum (ER) is intimately involved in protein processing.
Introduction
Protein S-glutathionylation is increasingly recognized as an important mechanism underlying redox regulation of signaling pathways with downstream effect on numerous cell functions (1, 2) . Cysteine residues localized in a basic environment (vicinal to Lys, Arg, or His) can have low pK a values, making them targets for the addition of glutathione (GSH), that is, can be S-glutathionylated. This modification adds f305 Da and introduces a net negative charge to the protein (as a consequence of the addition of Glu). Critical in ascribing any regulatory function to this process is the reversibility of S-glutathionylation by small-molecule proteins such as glutaredoxin and sulfiredoxin (3) (4) (5) . Our recent studies suggest that glutathione S-transferase k is involved in mediating the forward reaction of this cycle (6) . Glutaredoxin is reportedly involved in both forward and reverse steps (7) . Protein disulfide isomerase (PDI) is a CXXC motif-containing protein implicated (albeit in a minor role) in deglutathionylation (8) . PDI is a 57-kDa member of the thioredoxin superfamily organized into five domains (a, b, b ¶, a ¶, and c) with a COOH-terminal KDEL sequence that targets it to the endoplasmic reticulum (ER; ref. 9) , where it is involved in protein folding through disulfide bond formation and isomerization. PDI contains two active sites in the a and a ¶ domains, each having two conserved cysteine residues within the motif CGHC that cycle between oxidized (disulfide) and reduced (dithiol) states (10) . PDI has enzymatic functions that facilitate correct folding of proteins in the ER, for example, isomerase activity that catalyzes the rearrangement of incorrectly formed disulfide bonds and oxidase activity that introduces disulfides into proteins. PDI can also participate in multimeric protein clusters as a subunit of prolyl-4-hydroxylase and microsomal triglyceride transfer protein. In addition, cell surface PDI can be involved in cellular entry antigen processing (11) , complexes with integrin receptor in regulating cell adhesion (12) , glioma cell invasion (13) , attachment and infectivity of Chlamydia (14) , promotion of disulfide bond rearrangements in HIV-1 envelope protein that accompanies viral entry (15) , and may even be a determinant of drug resistance in malignant B lymphocytes (16) . O 2 -[2,4-dinitro-5-(N-methyl-N-4-carboxyphenylamino)phenyl]1-(N,N-dimethylamino)diazen-1-ium-1,2-diolate (PABA/NO) is among a series of prodrugs that incorporate diazeniumdiolate anions that release nitric oxide (NO) in a kinetically favorable manner resulting in nitrosative stress in cells (17, 18) . Although NO has significantly broad biological consequences in mammalian cells, we have been interested in its capacity to induce S-glutathionylation of proteins. Moreover, PABA/NO has antitumor potential both in vitro and in mice (19) , suggesting that there is value in developing this agent as a chemotherapeutic. As such, there is a need to understand how its pharmacologic effects may confer cytotoxicity.
Many anticancer drugs have electrophilic centers that can cause direct and indirect oxidative or nitrosative stress. These agents tend to have relatively nonspecific intracellular targets that when affected result in apoptotic cell death. Recently, a new consensus is emerging that the ER may be a common target for unrelated electrophilic species (1) . Dysregulation of ER homeostasis may cause a disruption of protein folding with the consequence that misfolded proteins may accumulate in the ER lumen and trigger activation of the unfolded protein response (UPR). Drug-induced disruption of the components of the various steps that constitute this pathway may play a pivotal role in inducing cell death, particularly in tumor cells. As a consequence, there is a need to clarify those molecular events that may link drug effects with aberrations in the UPR and produce cytotoxicity.
Stress emanating from the ER results in the accumulation of unfolded or misfolded proteins such that hydrophobic amino acid side chains are exposed on the protein's surface. This ''misfolding'' can result in a protein that does not maintain native interactions or, alternatively, forms insoluble aggregates. Protein folding in the ER is a crucial process and multiple signaling pathways have evolved to ensure quality control. The UPR leads to a cascade of transcriptional and translational events that include three mechanisms: transcriptional activation of UPR-induced proteins (including PDI and other chaperones), translational attenuation to decrease the flux of nascent polypeptides imported, and ERassociated degradation of terminally misfolded proteins via translocation to the cytosol for proteasomal degradation. The ER membrane contains three signal-transducing proteins that modulate the UPR: pancreatic ER kinase (PERK), activating transcription factor, and inositol requirement 1 (IRE1). Each is negatively regulated during homeostasis by a glucose-regulated protein 78/BiP through protein-protein interactions. An accumulation of unfolded or misfolded proteins results in the dissociation of BiP and activation of the membrane proteins. PERK activates an immediate response to ER stress that results in a transient attenuation of mRNA translation through phosphorylation of eukaryotic initiation factor, eIF2. PERK is associated with activation of two transcription factors, activating transcription factor 4 and NF-E2-related factor, which regulate downstream UPR genes and antioxidant cellular defense pathways. IRE1 is a site-specific endonuclease that cleaves a small intron in the mRNA of X-box protein 1 (XBP-1), a bZIP transcription factor, leading to mRNA stabilization. Both IRE1 and activating transcription factor 6 mediate the UPR through regulation of gene products with ER and antioxidant stress response elements.
When the UPR is unable to counterbalance the protein folding capacity, apoptotic pathways are activated (20) . UPR-induced apoptosis involves activation of c-Jun NH 2 -terminal kinase (JNK) and dissociation of the TRAF2-apoptosis signal-regulating kinase 1 complex and transcriptional activation of the gene for C/EBP homologous protein (CHOP). IRE1 and activating transcription factor 6 bind to the promoter of the apoptotic protein, CHOP. CHOP is a 29-kDa protein that was also described as growth arrest-and DNA damage-inducible gene 153. CHOP can be phosphorylated and activated on Ser 79 and Ser 82 by the p38 mitogen-activated protein kinase family and leads to cell cycle arrest (21) . Overexpression of CHOP leads to Bax translocation from the cytosol to the mitochondria. IRE1 has also been shown to be activated itself by proapoptotic Bcl-2 members, Bax and Bak, through protein-protein interactions in the cytoplasmic domain (22) . Bax and Bak have been localized in the mitochondria and ER membrane where they are proposed to contribute to membrane permeability (23) .
Using a broad-spectrum proteomic approach, we have shown previously that PDI is S-glutathionylated when HL60 cells are exposed to PABA/NO (24) . In the present study, we examine the specific susceptible molecular targets within PDI and how they may alter structure and function with cellular consequences that may directly invoke the UPR.
Materials and Methods
Chemicals. Reduced GSH, oxidized GSH, and the MTT reagent were purchased from Sigma. 3-Amino-4-aminomethyl-2,7-difluorofluorescein diacetate was purchased from Invitrogen. Thapsigargin was purchased from Calbiochem. PABA/NO was a gift from Dr. Larry Keefer (Chemistry Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute-Frederick). Antibodies were purchased from the following sources: anti-PDI (Affinity BioReagents); anti-glutathionylation (Virogen); antiphospho-JNK (Promega); anti-PERK, anti-eukaryotic initiation factor 2, phospho-specific PERK, and eIF2 (Santa Cruz Biotechnology); and anti-JNK1/2, BiP, CHOP, and LC3 (BD Biosciences Pharmingen).
Cell lines and cell culture. The human ovarian (SKOV3) and leukemia (HL60) cancer cell lines were purchased from the American Type Culture Collection and grown as recommended by the supplier. Cells were maintained in RPMI (HL60) or McCoy's (SKOV3) containing 10% FCS, 100 Ag/mL streptomycin, 100 units/mL penicillin, and 2 mmol/L L-glutamine at 5% CO 2 and 37jC. Cells (5 Â 10 5 per treatment group) were plated 24 h before drug treatment.
Protein preparation. Cells (5 Â 10 5 per treatment group) were harvested and washed with PBS. Cell pellets were suspended in lysis buffer [20 mmol/L Tris-HCl (pH 7.5), 15 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton X-100, 2.5 mmol/L sodium pyrophosphate, and 1 mmol/L h-glycerophosphate with freshly added protease and phosphatase inhibitors, 5 mmol/L NaF, and 1 mmol/L Na 3 VO 4 ] and incubated for 30 min on ice. Lysates were sonicated for 10 s and centrifuged for 30 min at 10,000 Â g at 4jC. Protein concentrations in the supernatant were assayed with the Bradford reagent (Bio-Rad) using IgG as a standard.
Immunoblot analysis. Equivalent amounts of protein were electrophoretically resolved under nonreducing conditions on 10% SDS-PAGE gels; unmodified proteins were separated under reducing conditions. Proteins Table 1 . Primer sequences used in the real-time PCR nonfat dried milk for 1 h. Membranes were incubated with the indicated antibody (blocking buffer containing 5% nonfat dried milk) at stated dilutions overnight at 4jC, washed three times with PBS for 15 min, and incubated with the appropriate secondary antibody conjugated to horseradish peroxidase for 1 h. The membranes were washed three times and developed with enhanced chemiluminescence detection reagents (Bio-Rad). The blots were scanned with a Bio-Rad ChemiDoc system and visualized with a transilluminator. The images were stored in a TIFF format. The relative intensity of bands was evaluated using Quantity One software (version 4.5.2; Bio-Rad) and plotted as arbitrary units in relation to actin. Immunoprecipitation of PDI. SKOV3 cells were treated with 0 or 25 Amol/L PABA/NO for 4 h. Cell lysates (500 Ag) from control and treated cells were precleared with protein A/G plus-agarose (Santa Cruz Biotechnology) in the presence or absence of nonspecific IgG. PDI was precipitated with the anti-PDI antibody (1:100) at 4jC overnight. Before SDS-PAGE, the samples were heated to f95jC for 10 min in nonreducing sample loading buffer.
In vitro S-glutathionylation of PDI. Recombinant human PDI in the expression vector pET-28a was provided by Dr. Lana Lee (University of Windsor) and expressed using the Escherichia coli strain BL21 (DE3) as described previously (25) . PDI (2 mg/mL; >95% homogeneous) in 20 mmol/L phosphate buffer (pH 7.4) was incubated for 1 h at room temperature as follows: (a) control, (b) 25 Amol/L PABA/NO and 1 mmol/L GSH, (c) 25 Amol/L PABA/NO, and (d) 1 mmol/L GSH. Excess PABA/NO and GSH were eliminated through Biospin-6 size exclusion micro-spin columns (Bio-Rad) with 20 mmol/L PBS. Nitrosylation and S-glutathionylation were detected by immunoblot. Control and drug-treated samples were evaluated by mass spectrometry, circular dichroism, and fluorescence scanning.
Identification of the target cysteine modifications of PDI. PDI from control and drug-treated cells were separated by SDS-PAGE under nonreducing conditions. Protein bands of interest were excised and subject to LysC digestion. The peptides were analyzed by mass spectrometry at the Proteomics Core Facility of the Medical University of South Carolina. The digested fragments were separated by high-performance liquid chromatography and 20 AL of the digested sample were injected with a Famous autosampler (LC Packings) onto a 75 Am Microtech Scientific C18 RP column. The peptides were eluted during a 30 min gradient from 2% to 70% AcN with 0.2% formic acid using a 180 nL/min flow rate with an Ultimate pump (LC Packings). The eluted peptides were detected on a Finnigan LTQ linear ion trap mass spectrometer operated in data-dependent acquisition mode with dynamic exclusion enabled. Protein identification was done using software from the National Center for Biotechnology Information protein database.
Spectroscopic analysis of PDI in vitro . The effect of PDI S-glutathionylation on enzyme secondary structure was examined by circular dichroism where measurements were carried out on a 202 AVIV Associates using a semi-micro quartz rectangular 1 Â 10 Â 40 mm cuvette. Native and S-glutathionylated PDI samples were maintained at 22jC using a Pelletier element. Spectra were recorded while scanning in the far-UV region (190-260 nm), with bandwidth of 1.0 nm, step size of 1.0 nm, integration time of 30 s, and with three repeats. The output of the circular dichroism spectrometer was recalculated according to the protein concentration, amino acid content, and cuvette thickness into molecular ellipticity units (degrees/cm 2 /dmol). Protein tryptophan fluorescence was recorded on a F 2500 spectrofluorometer (Hitachi) using 10 Â 10 Â 40 mm quartz cuvette, excitation and emission slits were 2.5 and 5.0 nm, respectively. The excitation wavelength was 295 nm to minimize an effect of protein tyrosines and phenylalanines. Background spectra were subtracted from final emission of the protein. Microplate Multimode Reader (Turner BioSystems) with a ''Blue'' optical kit (excision = 490 nm, emission = 510-570 nm) and standard kinetics mode. The measurements were done at room temperature in 96-well Fluotrac 200 black microplates (VWR, Greiner Bio-One North America). The starting point for the kinetic experiments began f2 min after the addition of PABA/ NO (e.g., the time necessary for additions of drug to all wells). All fluorescent measurements were corrected using the following controls: fluorescence of unlabeled cells, fluorescence changes in labeled cells without any addition of PABA/NO, and the effect of addition of solvents on the cellular fluorescence without probes.
PDI activity assay. PDI was incubated with various concentrations of PABA/NO (0-100 Amol/L) and 1 mmol/L GSH for 30 min at 37jC. The activity of PDI was monitored using the turbidimetric assay of insulin disulfide reduction. Briefly, 0.25 Amol/L purified human PDI was added to a solution of insulin (0-250 Amol/L) and GSH (500 Amol/L) in a 0.1 mol/L K 2 HPO 4 containing 2 mmol/L EDTA (pH 7.0). The increase in turbidity was monitored (k = 630) at 30 s intervals for 30 min. Three independent experiments were conducted. Mean F SE was computed for each group.
Cytotoxicity assays. Ten thousand cells were seeded in 96-well plates in 50 AL medium. Increasing drug concentrations were added to a final volume of 100 AL and maintained in drug for 72 h. Following drug exposure, cell viability was assayed by the MTT conversion assay. Each drug concentration was represented in quadruplicate and three independent experiments were conducted. Mean F SE was computed for each group.
RNA isolation and quantitative real-time reverse transcription-PCR. Total RNA was isolated and DNase I treated using the RNeasy mini kit according to the protocol of the manufacturer (Qiagen). cDNA was prepared using either the iScript cDNA synthesis kit (Bio-Rad) or the RT 2 First Strand Kit (SABiosciences) according to the protocols of the manufacturers. All quantitative real-time reverse transcription-PCR were done using the MyiQ system (Bio-Rad) and iQ SYBR Green Supermix (Bio-Rad) or SYBR Green/ fluorescein PCR Master Mix (SABiosciences) according to the protocols of the manufacturers. Actin mRNA levels were used to normalize differences in cDNA levels and the data are expressed using the DDCt method (26). Primers were designed using Primer3 software (27) and primer sequences are listed in Table 1 . All reactions were done in triplicate and data were analyzed using the 2 ÀDDCT method (26). Glyceraldehyde-3-phosphate dehydrogenase and actin was used as a gene control to normalize differences in cDNA between groups. Statistical analysis. Mean, SD, and SE for at least three experiments were calculated for each treatment group. These data were analyzed for statistically significant differences between groups with Student's t test using SigmaStat 3.5 (Systat Software). Differences were considered statistically significant if P < 0.05.
Results
PABA/NO treatment leads to NO generation, cytotoxicity, and S-glutathionylation of PDI in SKOV3 cells. PABA/NO elicits Figure 2 . Active site cysteines in hPDI are targets for S -glutathionylation. hPDI was treated with 1 mmol/L GSH and/or 25 Amol/L PABA/NO for 1 h. S-glutathionylation or nitrosylation of PDI was detected by immunoblot (A). To identify specific cysteine residues that are targets for S-glutathionylation, control and PABA/NO-treated hPDI were digested with LysC under nonreducing conditions and analyzed by tandem mass spectroscopy. Two fragments corresponding to the active sites (43-57 and 387-401) were detected in the treated samples (B and C, respectively). Each result was consistent with a single S-glutathionylated modification [+305.6] with a probability of 8.7e-002 and 7.4e-002, respectively.
antitumor activity in cisplatin-sensitive and cisplatin-resistant ovarian cancer xenografts (19) . The following studies were designed to validate that PDI is a pharmacodynamic marker of PABA/NO in ovarian cancer cells. Figure 1 shows that PABA/NO treatment leads to dose-dependent cytotoxicity and NO generation in human ovarian cancer cells, SKOV3 (Fig. 1A and B) . We have reported previously that the toxic effects of PABA/NO treatment are attributed to S-glutathionylation of cellular proteins in HL60 cells, among which is PDI (24) . Consistent with these findings, PABA/NO treatment caused S-glutathionylation of several proteins in SKOV3 cells (Fig. 1C) . One of the high molecular weight proteins had a mobility characteristic of PDI. Immunoprecipitation of PDI followed by immunoblot for S-glutathionylated moiety confirmed that PDI is S-glutathionylated (Fig. 1D) . Lane 4 shows that PABA/ NO treatment enhanced the extent of PDI S-glutathionylation in a manner that was reversible by the reducing agent DTT (lane 5). The bottom panel shows that PDI itself was present only in lanes 1, 4, and 5.
Active site cysteines in hPDI are targets for S-glutathionylation. Using human full-length PDI, we confirmed via immunoblot and mass spectroscopy that drug treatment leads to S-glutathionylation of cysteine residues. PDI (1 Amol/L) was incubated in 50 mmol/L NaPO 4 (pH 7.4) at 37jC for 30 min with 100 Amol/L PABA/NO or 10 mmol/L GSH or both. The samples were separated by SDS-PAGE under nonreducing conditions. The gels were transferred overnight to polyvinylidene difluoride membrane and immunoblotted with anti-S-glutathionylation ( Fig. 2A) , anti-Snitrosylation, and anti-PDI antibodies. Nitrosylation was not detected by Western blot. Native and S-glutathionylated PDI was subjected to LysC digestion, the resultant fragments analyzed under nonreducing conditions by tandem mass spectroscopy. Within two distinct peptides (residues 43-57 and 387-401), a mass increase of 305.6 was consistent with the S-glutathionylation of one cysteine residue in each fragment (see Fig. 2B, asterisks) .
S-glutathionylation of the active site cysteines on PDI alters structure. We evaluated the effects of S-glutathionylation of PDI on its secondary structure. The circular dichroism spectrum (200-240 nm) of S-glutathionylated PDI was quite similar to native protein (Fig. 3A) but consistent with a small decrease in the a-helix content (206-220 nm) of the protein. Based on the crystal structure of PDI, the sulfhydryls of cysteine residues 61 and 64 are proximal to a tryptophan at position 60. Consistent with the known quenching effect of a disulfide bond on adjacent tryptophanyl fluorescence, the intrinsic tryptophanyl fluorescence of PDI was measured (6) . Our data showed a substantial PDI tryptophanyl fluorescence decrease corresponding with S-glutathionylation (Fig. 3B) . These results indicate the dynamic nature of Sglutathionylation resulting in spatial disulfide/sulfhydryl equilibria. Moreover, a hypsochromic shift of emission maximum f4 nm after protein S-glutathionylation indicates some shielding of Trp 38 from a polar environment through Cys 61 and/or Cys 64 Sglutathionylation (Fig. 3D) . The possible disulfide that may form at positions Cys 90 and Cys 97 is too distal from the tryptophan residue to have an effect. These fluorescent analyses confirm that S-glutathionylation affects the tertiary structure of PDI.
PDI reductase activity was assessed by insulin turbidity assay (Fig. 3C ). Native and S-glutathionylated PDI were applied to Micro Bio-Spin columns to remove excess PABA/NO and GSH. PDI proteins (250 nmol/L) were then incubated at 25jC with 1 mg/mL insulin in NaPO 4 in the presence of 1 mmol/L DTT. The precipitation of reduced insulin was recorded every 2 min for 30 min at 650 nm. After subtracting the basal rate of DTT-mediated insulin reduction, the specific activity of native PDI in this assay was 1,518 F 258 (units/ min/mgP). Moreover, the catalytic activity of PDI is diminished in a dose-dependent manner following PABA/NO treatment (Fig. 3C) . We propose that S-glutathionylation of PDI may be an upstream event that is sufficient to contribute to the accumulation of unfolded proteins and thereby trigger activation of the UPR.
S-glutathionylation of PDI is concurrent with activation of the UPR. Translational attenuation is a cellular consequence of ER stress and is mediated by phosphorylation of PERK and eIF2. By treating SKOV3 cells with either PABA/NO or the UPR-inducing agent, thapsigargin, at approximate IC 50 concentrations (Fig. 4A) , it was possible to show that cytotoxic effects were temporally accompanied by increases in phosphorylation of JNK, PERK, and eIF2. Total protein levels of these products were unaffected (Fig. 4B) .
Paradoxically, transcriptional activation and translation of UPR genes also occurs under ER stress. We monitored drug-induced changes in transcript levels for several UPR genes at 0, 4, and 24 h following PABA/NO treatment. Cleavage of the transcription factor XBP-1 was detected as early as 2 h following treatment (Fig. 4B) . Using real-time PCR, it was possible to quantitate a timedependent transcriptional activation of the ER resident proteins BiP, GRP94, ERO1, and PDI, all of which showed between 5-and 10-fold induction (Fig. 4D) . PABA/NO is cytotoxic to cancer cells and we show a 9-fold induction of the proapoptotic transcription factor, CHOP, which is also a UPR effector. Using immunoblot analysis, we confirm that the protein levels for BiP and CHOP are up-regulated (Fig. 4D) .
In the preclinical characterization of PABA/NO, we discovered that PDI is S-glutathionylated in HL60 cells following treatment (24). These studies showed that PDI is a molecular target of PABA/ NO in SKOV3 cells and suggest that the mechanism of cell death is attributed to activation of the UPR. These studies were extended to HL60 cells and it is illustrated in Fig. 5 how PABA/NO treatment can lead to nitrosative stress and cell death through induction of the UPR.
Discussion
In designing these investigations, we have sought to link the mechanism of cytotoxic action of a NO-releasing drug with the induction of an ER stress response in target cells. At the same time, drug-induced S-glutathionylation of PDI regulates its activity and facilitates upstream regulation of the UPR. It seems plausible that this post-translational modification of PDI may contribute to how the ER detects stress and may determine whether a cell survives a treatment that can produce a UPR event. Activation of the UPR is mediated by at least three ER proximal sensors (IRE1, PERK, and activating transcription factor 6) and our data show that PABA/NO affects the expression of each of these. The coordination of the PDI and downstream signaling events provides an integration point for the functional determination of cell survival pathways. Several recent reports have suggested that cancer pathology and the response of cancer cells to drugs may be dependent on an integration of ER stress response pathways (28) . It is also worth noting that PDI can have important chaperone functions that depend on formal protein-protein interactions (29, 30) .
When S-glutathionylation and PERK activation by PABA/NO were compared to a known ER stress-inducing agent thapsigargin, some significant similarities were observed. The mechanism of action of thapsigargin is attributed to inhibition of the Ca 2+ pump protein located in ER membranes (SERCA; ref. 31 ). As such, it is intriguing that thapsigargin induces S-glutathionylation with kinetics similar to PABA/NO, notably with proteins in the 50 to 60 kDa range. This is consistent with the hypothesis that Sglutathionylation is an important signaling event associated with stress emanating from the ER. A significant pool of PDI in SKOV3 cells undergoes S-glutathionylation in a time-dependent manner following PABA/NO. Immunoblots detected three bands in the PABA/NO-treated sample that correspond to monomeric PDI, suggesting that multiple sites on the protein may be modified. Interestingly, larger molecular weight species were also present, suggesting that multimers might undergo redox modification.
The cytotoxic effect of PABA/NO-induced nitrosative stress has been linked to JNK activation that leads to apoptosis (24) . Our present studies provide further insight into the mechanism and Figure 5 . Mechanism of PABA/NO-induced antitumor activity is attributed to activation of the UPR. The mechanistic studies were extended to HL60 cells in which S-glutathionylation of PDI was originally identified following PABA/NO treatment. HL60 cells were treated with 0 to 50 Amol/L PABA/NO for 1 h. Translational attenuation through activation of PERK was evaluated in HL60 cells following drug treatment (A). Protein lysate (50 Ag) was separated by SDS-PAGE and analyzed by immunoblot for levels of JNK and PERK. The membranes were stripped and probed for total levels of phosphorylated proteins. Activation of XBP-1 was detected by PCR (B). RNA was extracted at various time points and analyzed with primers specific to XPB-1. A 398-bp fragment corresponds to the cleaved and active form of XBP-1. Transcriptional activation of NO-and UPR-inducible proteins was evaluated with SYBR Green reverse transcription-PCR methods (C ). HL60 cells were treated with 25 Amol/L PABA/NO for 4 to 6 h (white columns ) or 24 h (gray columns ). The relative quantity was measured as the ratio of the mRNA expression of the target gene to that of glyceraldehyde-3-phosphate dehydrogenase. Mean F SD for three independent experiments. suggest that nitrosative stress elicits cell damage through ER stress. To show mechanism, two of the three signaling events that initiate the UPR, PERK, and IRE1 activation were up-regulated by PABA/ NO. An accumulation of unfolded or misfolded proteins leads to the dissociation of BiP from PERK and IRE, allowing phosphorylation and activation of both proteins. The kinase activity is dependent on conformational changes that occur when PERK is phosphorylated and this occurred in a dose-and time-dependent manner in SKOV3 cells following PABA/NO. Validation that PABA/ NO activates UPR responsive genes was provided by the 2-to 10-fold increased expression of PDI, ERO1, BiP, and CHOP. Collectively, these data suggest that S-glutathionylation of PDI diminishes the folding capacity within the ER and mediates the UPR.
The link between S-glutathionylation of PDI and the UPR presents an important mechanistic connection with respect to cellular cytotoxic effects of PABA/NO and thapsigargin. We envision the following model for how PABA/NO may induce cytotoxic effects. Activation of PABA/NO occurs intracellularly in the presence of GST and GSH (17, 32) . This releases NO that through nitrosative stress causes direct or indirect S-glutathionylation of several protein clusters, among which are those involved in protein folding (1) . By comparing PABA/NO with thapsigargin, it is possible to draw parallels between the mechanisms of action of the two drugs. Recently, we have shown that thapsigargin and PABA/NO share the capacity to alter calcium flux from the ER to cytosol. 3 Thapsigargin has been categorized as an inhibitor of SERCA, but there is no obvious metabolite of the drug that is likely to produce either oxidative or nitrosative stress (33) . Thus, it is unexpected that thapsigargin causes S-glutathionylation and has implied a cause-effect relationship of this post-translational modification and calcium homeostasis, a subject of another study. 3 Implications for PDI function should also consider that our present study has not drawn distinction between the cellular localization of PDI. Although the majority of PDI is located in the ER, there are reports that PDI may also regulate the cell surface redox environment (16, 34) . This can be important in cell adhesion, antigen processing, or viral entry (11, 12, 15) . S-glutathionylation of cell surface proteins by oxidized GSH alters both extracellular and intracellular redox homeostasis in HL60 cells (35) .
PDI is involved in both rapid metabolism of GSNO and intracellular NO delivery, and during this process, PDI is itself altered by thiol modification (36) . Following treatment of cells with diethylamine-NO, PDI was shown to be subject to nitrosylation (37) . Although we did not detect nitrosylation of PDI following PABA/NO (data not shown), such a modification may readily be subject to rapid conversion to S-glutathionylation (2, 38) . The functional implication of this post-translational modification is that PDI has a reduced activity for the period that the cysteine residue is S-glutathionylated. Our previous results estimate that the half-life of the S-glutathionylation modification is f3 h (6). In cataloguing existing literature, at least six clusters of proteins seem to be subject to S-glutathionylation, cytoskeletal/structural, energy metabolism/glycolysis, calcium homeostasis, signaling kinases and phosphatases, redox homeostasis, and protein folding (1) . Similar to phosphorylation, cysteine modification is critical to normal cellular signaling and its dysregulation is linked with multiple diseases. From this perspective, there may well be a general link between diseases associated with ER stress and the accumulation of S-glutathionylated PDI. Finally, it is worth noting that drugs such as Velcade essentially have an indirect effect on the UPR through interference with the proteasomal machinery. It appears that PABA/NO has a mechanism of action that induces a UPR cell death more directly through PDI as an intermediary.
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